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Genomic and oncogenic preference of HBV
integration in hepatocellular carcinoma
Ling-Hao Zhao1,2,*, Xiao Liu3,*, He-Xin Yan1,2,*, Wei-Yang Li3,4,*, Xi Zeng3,5,*, Yuan Yang1,*, Jie Zhao1,
Shi-Ping Liu3, Xue-Han Zhuang3, Chuan Lin1, Chen-Jie Qin1,2, Yi Zhao4, Ze-Ya Pan1, Gang Huang1, Hui Liu1,
Jin Zhang1, Ruo-Yu Wang1, Yun Yang1, Wen Wen1,2, Gui-Shuai Lv1,2, Hui-Lu Zhang1,2, Han Wu1,2, Shuai Huang1,
Ming-Da Wang1,2, Liang Tang1,2, Hong-Zhi Cao3, Ling Wang6, Tin-Lap Lee5, Hui Jiang3, Ye-Xiong Tan1,2,
Sheng-Xian Yuan1, Guo-Jun Hou1, Qi-Fei Tao1, Qin-Guo Xu1, Xiu-Qing Zhang3, Meng-Chao Wu1, Xun Xu3,
Jun Wang3,7, Huan-Ming Yang3, Wei-Ping Zhou1 & Hong-Yang Wang1,2,8
Hepatitis B virus (HBV) can integrate into the human genome, contributing to genomic
instability and hepatocarcinogenesis. Here by conducting high-throughput viral integration
detection and RNA sequencing, we identify 4,225 HBV integration events in tumour and
adjacent non-tumour samples from 426 patients with HCC. We show that HBV is prone to
integrate into rare fragile sites and functional genomic regions including CpG islands.
We observe a distinct pattern in the preferential sites of HBV integration between tumour and
non-tumour tissues. HBV insertional sites are signiﬁcantly enriched in the proximity of
telomeres in tumours. Recurrent HBV target genes are identiﬁed with few that overlap. The
overall HBV integration frequency is much higher in tumour genomes of males than in
females, with a signiﬁcant enrichment of integration into chromosome 17. Furthermore,
a cirrhosis-dependent HBV integration pattern is observed, affecting distinct targeted genes.
Our data suggest that HBV integration has a high potential to drive oncogenic transformation.
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H
epatocellular carcinoma (HCC) ranks ﬁfth in global
cancer incidence and represents the third leading cause
of cancer deaths1. Chronic infection with hepatitis B or C
virus (HBV or HCV) represents the major risk factors for the
development of HCC2,3. Unlike HCV, an RNA virus which never
integrates into the host genome during its lifecycle, HBV–DNA
frequently integrates into host genome and progressively
contributes to hepatocarcinogenesis4. Integration of HBV DNA
into the host genome causes genetic damage and chromosomal
instability, which is known to be selectively advantageous for
tumour progression5. The deregulated host gene expression or a
subset of rearranged integration sites has been shown to play a
key role in HCC development6. In addition, expression of viral
proteins such as X protein and S antigen as well as their
oncogenic mutants may further enable the acquisition of
neoplastic characteristics. Previous isolation of HBV integration
sites using PCR-based methods7 and more recent use of deep
sequencing in a small size cohort of HCC patients suggests that
the HBV insertional sites occurred randomly throughout the
genome, leading to the presumption that there were no
preferential sites of integration. However, recurrent HBV
integrations have recently been identiﬁed in a large cohort of
HCC patients through the application of high-throughput next-
generation sequencing8–11. Although recurrent integrations still
represented a minority of the total events characterized, the
occurrence of recurrent sites of insertion suggests that HBV may
have preferential integration sites associated with distinct
biological consequences and clinical outcomes. The most
common HBV integration event is located at the telomerase
reverse transcriptase gene (TERT), which is thought to confer
early clonal advantage during chronic HBV infection. Other
frequently targeted genes such as KMT2B and CCNE1 have
recently been identiﬁed as new classes of genes not previously
known to play a causal role in cancer10. However, it is of note that
recurrent HBV integration sites identiﬁed in previous studies may
only represent a minority of recurrent events.
HCC has a male predominance and is closely related to
cirrhosis12–14. Males with chronic HBV infection are at higher
risk of developing HCC compared with females. In fact, the sex
difference becomes apparent from the stage of early chronic
infection, where the male-to-female ratio increased from 1.2 in
asymptomatic carriers to 6.3 in chronic hepatitis and 9.8 in HCC
in a Taiwanese study15,16. On the other hand, although the
majority of HCC patients with HBV infection have concurrent
liver cirrhosis, the integration of the viral genome into infected
cells can directly induce a non-cirrhotic liver to develop HCC.
Despite extensive research, the precise mechanisms whereby
HBV integration contributes to cirrhotic and non-cirrhotic
hepatocarcinogenesis as well as gender disparity remain largely
unclear due to technical limitations and a lack of clinical
annotation.
In this study, we conducted high-throughput viral integration
detection (HIVID), a highly sensitive method for assaying viral
insertion compared with the whole-genome sequencing, and
analysed 426 HBV-associated HCC patients with or without
cirrhosis17. Our results revealed an excessive HBV integration
across the host genome with particular genomic pattern in a
gender or cirrhosis-dependent manner.
Results
Characteristics of the HBV integration events in human genome.
To search for HBV integration sites across the HCC genome and
decode viral–host interactions, we conducted HIVID analysis
on tumour and adjacent non-tumour liver genomes extracted
in a cohort including 426 clinically and pathologically
well-characterized HBV-associated HCC cases: 298 with cirrhosis
and 128 without cirrhosis; 360 males and 66 females
(Supplementary Figs 1–3 and Supplementary Table 1). HBV
integrations were effectively detected at a single base pair
resolution using HBV capture sequencing. A total of 4,225 HBV
integration breakpoints were discovered. To conﬁrm the newly
discovered events, we randomly selected 180 putative insertions
for PCR analysis and successfully validate 81.1% of these
integration sites (Supplementary Data 1). Despite a handful of
integration hotspots, most insertion sites are distributed in an
apparently random manner throughout the genome (Fig. 1a). The
integrations maps generated reveal a heterogeneous, widespread
viral integration landscape in tumour as well as in non-tumour
liver tissue from HCC patients. However, HCC tumour samples
and their adjacent non-tumour liver tissues exhibit strikingly
distinct patterns of viral insertion. Following the known
association between HBV infection and HCC development,
tumour samples harbour a much higher frequency of integrated
reads than the non-tumour samples. The total HBV integration
breakpoints in tumour and non-tumour samples are 3,486 and
739 events, respectively (Supplementary Data 2 and 3). Of 426
paired samples, 76.9% tumour and 37.6% non-tumour tissues
contained HBV integration. The average number of integration
sites in tumour tissues and adjacent non-tumour liver tissues are
10.6 and 4.6, respectively, (P¼ 3.3 10 6, unpaired Student’s
t test; Supplementary Fig. 4). Analysis of the distribution of
hotspots across the human genome further conﬁrms the pre-
valence of HBV integrations in tumours. Among the 826 and 303
genes with HBV insertions (intragenic region and upstream
10 kb) detected in tumour and non-tumour tissues, respectively,
only 64 genes were shared by the tumour and non-tumour
samples, underscoring that integration patterns are distinct in the
tumour and normal samples (Fig. 1a and Supplementary Data 4).
Correlation between HBV integration and genome instability.
Statistically signiﬁcant enrichment of integration was observed
within CpG islands in tumours compared with normal samples
(Fig. 1b). The integration frequency dramatically decreased in
genomic loci moving away from CpG islands. However, no
apparent prevalence in integration was observed in transcription
factor binding site and transcription start site (Supplementary
Fig. 5). HBV was also prone to integrate into rare fragile sites, but
only in a tumour-speciﬁc context (Fig. 1c). These results suggest
preferential HBV integration into chromosomal repetitive or
fragile regions could provide a selective advantage during
tumorigenesis, rather than representing by product event from
random insertion. More importantly, HBV integration sites were
signiﬁcantly enriched in the proximity of telomere in the tumour
samples but not in the non-tumour samples (Fig. 2), suggesting
that HBV favours targeting chromosomal elements critical for the
maintenance of chromosome stability.
As integration of HBV–DNA into the human genome is
considered an early event during hepatocarcinogenesis and can
induce chromosomal instability, we next analysed the distribution
of HBV breakpoints across individual chromosomes. Although
relatively random distribution of integration sites was observed
in non-tumour samples, statistically signiﬁcant enrichment of
integration sites on chromosome 5, 16, 17 and 19 was observed in
tumour samples (Fig. 2), suggesting that preferential integration
exists at the chromosomal level.
Expression of target genes and effect to HBV integration. The
comprehensive HIVID analysis in this large-sample cohort has
allowed us to investigate the frequency of recurring tumour-
associated integrations in genes. Notably, there were 88 and 17
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genes recurrently affected (nZ2) by HBV integration in the
tumour and non-tumour samples, respectively, which has
dramatically expanded our understanding of integration sites of
HBV. Apart from the recurrent integrations previously observed
in TERT, MLL4 and CCNE1 genes, novel affected genes (PTPRD,
UNC5D, NRG3, CTNND2 and AHRR) were identiﬁed, and their
expressions were altered at both the transcript and protein levels
(Supplementary Figs 6 and 7). Interestingly, these genes have
been reported to have oncogenic or tumour suppressive function.
In keeping with previously published ﬁndings, the expression
of some affected genes with oncogenic potential, including TERT
and KMT2B, showed increased expression following HBV
integration. Our results suggest that these novel affected genes
are, at least in part, functionally relevant to HBV insertion.
We noted that individuals with HBV integrations (BK40) in
the tumour displayed a signiﬁcantly shorter survival than
those without HBV integrations (BK¼ 0). Furthermore, HBV
integration led to an evident upregulation of TERT and patients
with HBV integration at TERT gene had signiﬁcantly poorer
survival (Fig. 3). Interestingly, tumour-enriched integration into
the promoter regions of genes was noted, as compared with the
non-tumour genomes (385/3486 versus 57/739; Po0.01, w2 test).
In contrast, the integration breakpoints were preferentially
located in the intron region in non-tumour samples
(Supplementary Fig. 8). This integration bias indicates that
HBV is prone to integrate into promoters in HCC tumours,
further affecting transcription of particular genes.
Breakpoints in HBV genome. To investigate the integration
mechanisms underlying viral–host interactions, we surveyed the
breakpoints on the HBV genome. Consistent with previous
reports, B40% of breakpoints were observed at nucleotides
1,400–1,900 around the 30-end of the HBx and 50-end of
the Precore/Core genes in both tumour and non-tumour
samples(Fig. 4a). To deconvolute HBV integration at the
transcriptional level, we randomly selected 12 tumour samples
for RNA sequencing and characterized the transcribed viral
elements corresponding to nucleotides 1,700–1,900 of HBV
genome(Supplementary Table 3). Interestingly, a peak of HBV
breakpoints in a region from 300 nt to 500 nt was noted at the
transcriptional level, where the S gene was located(Fig. 4b).
These viral breakpoints may not only rearrange viral DNA and
functional properties but also physically subvert normal control
of nearby cellular genes, thus leading to the dysregulation of
transcription network in HCC.
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Figure 1 | Distribution of HBV integration breakpoints throughout the human genomes in 426 paired samples. (a) Distribution of integration
breakpoints across the human genome in 426 paired samples. Each bar represents the sample frequency of HBV integration breakpoints at a particular
locus in the human genome (hg19). Tumour (red) and non-tumour (dark blue) samples with HBV integrations are shown on the inner and outer circles,
respectively. Histogram axis units represent number of samples. Some loci with a high frequency of integration are marked. GENE. (b) Comparison of the
breakpoints in the CpG island region of 426 paired samples. The expected (assuming uniform, random distribution, yellow) and the observed (actual
numbers, tumour: blue; normal liver tissue: purple) percentages of HBV integration breakpoints of tumour and non-tumour samples in CpG islands region
are shown. P values were calculated by w2 test. (c) Distribution of integration breakpoints in the fragile region (FR) of 426 paired tumor and non-tumor
tissues. The expected (assuming uniform, random distribution, yellow) and the observed (actual numbers, tumour: blue; normal liver tissue: purple) ratios
of HBV integration breakpoints in common fragile region, rare fragile region and non-fragile region are shown. P values were calculated by w2 test. Common:
common FR; rare: rare FR; NFRs: non-fragile regions.
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Next, we investigated the prevalence of various HBV genotypes
across our cohort. The sequence analysis of HBV–DNA from
426 patients with HBV integration revealed the predominant
integration of genotype C in 74.9% patients and genotype B in
remaining 13.4% patients. The distribution of HBV genotypes in
non-HCC liver tissues was similar to tumour tissues. We also
noted that the integration rate of B type was signiﬁcantly higher
than C type (Supplementary Fig. 9). No signiﬁcant correlation
between the circulating level of HBV–DNA and the frequency of
HBV integration was noted (Supplementary Fig. 10). However,
we observed that circulating HBe antigen level had a signiﬁcant
linear correlation with HBV integration in tumour tissues. This
suggests that the viral replication capacity could closely inﬂuence
the HBV integration in human genome (Supplementary Fig. 11).
In our analysis, we observed that multiple HBV fragments
could integrate into a single site within the human genome.
Further analysis demonstrated that, when compared with
non-tumour samples, the breakpoints within tumour samples
displayed more diversity with regard to the HBV integration
fragments. Although most of the breakpoints were integrated by
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Figure 3 | Clinical correlation analysis of HBV integration in HCC. (a) Kaplan–Meier survival curves for individuals with (BK40, n¼ 319) versus without
(BK¼0, n¼ 97) HBV integration breakpoints by log-rank test. Those who lacked prognostic information were excluded from the analysis (n¼ 10).
(b) Gene expression levels of TERT that frequently harboured HBV integrations in samples with versus without HBV integration events. Gene expression
was normalized by the corresponding adjacent, normal control and is represented as the tumour/normal gene expression level. P values of unpaired
Student’s t test are shown. In the box plots, the median (50th percentile) is the middle line, with the bottom and top of the box representing the 25th and
75th percentiles of the data, respectively. The ends of the whiskers represent the lowest and highest data within the 1.5 interquartile range (IQR). IQR was
deﬁned as the distance between the lower and upper quartiles of the data. (c) Kaplan–Meier survival curves for individuals with (n¼ 101) versus without
(n¼ 315) HBV integration in TERT by log-rank test.
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less than 2 types of HBV fragments, tumour tissues carried more
breakpoints integrated by more than 2 types of HBV fragments
than non-tumour tissues did (Supplementary Fig. 12), suggesting
an increased heterogeneity for HBV integration in tumours.
The mechanism of HBV integration has been thought to
involve double-strand break repair, linearized viral DNA
invasion/end joining and viral replication, but the details are
still unclear18. Microhomology (MH)-mediated DNA repair
pathways, including MH-mediated end joining, fork stalling
and template switching and MH-mediated break-induced repair
have been proposed to induce genomic rearrangements19,20 and
other viral insertion21. In light of these hypotheses, we searched
for the MH sequences between the cellular and the inserted
HBV DNA near the integration sites, and found they were
signiﬁcantly enriched with the increase of the MH length,
suggesting the potential involvement of MH-mediated
mechanism (Supplementary Fig. 13), which could be triggered
by the genomic instability/fragility near the integration sites
(Supplementary Fig. 14).
Association of HBV integration with sex and clinical outcome.
As HBV integrations may be speciﬁc biomarkers for prediction of
clinical outcomes, we analysed the association between viral
integration and clinicopathological parameters in HCCs (Fig. 5
and Supplementary Table 4). Consistent with a male pre-
dominance in HCCs, males had much higher HBV integrations
than females in tumour genomes (Supplementary Table 5).
Speciﬁcally, we observed that substantial genomic regions were
preferably integrated by HBV in males in Chromosomes 2 and
17, but not in females (Fig. 6), and HBV integrations in these
regions were closely associated with prognosis (Supplementary
Fig. 15). Notably, many genes in chromosome 17p are known to
play important roles in hepatocarcinogenesis22 including the
key tumour suppressor TP53 and master inhibitor of liver
regeneration MKK4 (refs 23–25). Furthermore, we found
integrations in males were prone to locate into the region of
core protein (P¼ 0.01, w2 test) in the HCC genome when
compared with females.
Correlation of HBV integration with Cirrhosis. Clinically, some
patients with HBV-related HCC have a lower incidence of
cirrhosis, suggesting that critical oncogenes or tumour suppressor
genes were involved in hepatocarcinogenesis without inﬂicting
chronic inﬂammation. Gene annotation revealed a cirrhosis-
dependent HBV integration pattern; that is, tumours arising from
non-cirrhotic liver displayed a signiﬁcantly enriched viral
integration in the vicinity of putative oncogenes or tumour
suppressors such as KMT2B, CCNE1 and AHRR compared with
those in the cirrhotic liver (Supplementary Data 5 ), suggesting
that constitutive activation or inactivation of these genes may
contribute to the early onset of HCC without cirrhotic responses.
Discussion
Here we demonstrate a large scale analysis of HBV–DNA
integration sites in liver cancer using HIVID approach.
Compared with whole-genome sequencing, HIVID combines
HBV fragment capture and massively parallel sequencing, thus
dramatically increases the detection efﬁciency and decreases
sequencing complexity and cost. In line with published results on
whole-genome sequencing of HBV-associated HCC, HBV
integration occurs frequently in both tumour and adjacent non-
tumour tissues, with signiﬁcantly higher insertion rates in
tumours8–11. Although integrations of HBV were once thought
to be random, our data highlights recurrent integrated regions
and greatly expands the list of affected genes. In addition to
frequent integrations at TERT, KMT2B and CCNE1, which
were known targets of HBV insertion, we discovered massively
new recurrent HBV integrations among 426 HCC patients.
A signiﬁcant percentage of them showed expression or function
abnormality in tumours and have been shown to be related to
cancer progression in other tumour types. Our data provide an
important amendment to our understanding of HBV impact on
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hepatocarcinogenesis, supporting the non-random integration
and selection process of HBV targeted genes.
As HBV integration is common and is associated with genomic
instability, we examined the distribution of insertion sites in
distinct genomic elements26,27. Not surprisingly, chromosomal
fragile sites, known sites of genomic rearrangement in cancer,
represent preferred sites for the integration of HBV. In addition,
HBV showed an evident preference for CpG islands, in which
DNA methylation often precedes the appearance of tumours and
are prone to additional chromosomal aberrations, such as loss of
heterozygosity. As virus negative tumours have fewer epigenetic
and genetic alterations28, epigenetic instability via CpG islands
methylation/demethylation may contribute to chromosomal
instability in HBV-related HCCs. More importantly, the
enrichment of HBV integration events was also observed in the
proximity of telomere, which plays an important role in
maintaining genome stability. Regardless of the mechanism,
dysfunction of telomere function can lead to extensive DNA
ampliﬁcation, large terminal deletions and generate many types
of rearrangements commonly associated with human cancers29.
Although speciﬁc sequence features near the fusion break-
points were not identiﬁed in the host genome, there were a
handful of hotspots in the tumour genome where multiple HBV
fragments could integrate. This is consistent with a non-random
integration model followed by a positive selection during
hepatocarcinogenesis. Other than HBx proteins surrounding
DR1 or DR2 sites, RNA sequencing revealed an enriched
expression and favoured integration of preS and S protein in
the tumour samples, in accordance with the role of the truncated
preS2/S protein in mediating stimulation of cellular genes,
in trans30.
Despite a signiﬁcant gender skew of HCC in male, little is
known about the difference of HBV integration between genders.
Herein, we show that HBV was prone to integrate in male tumour
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genome and, more importantly, had a chromosome preference.
HBV integration into chromosomes2 and 17 was favoured in
male tumours, the latter of which contains the TP53 gene and is
frequently lost in the human cancers. In addition to aberrations of
TP53 gene on chromosome 17p13.1, other genes on 17p13.3 may
also play a role in hepatocarcinogenesis22. Notably, located on
17p adjacent to the TP53 gene, MKK4 was recently identiﬁed as a
master inhibitor of liver regeneration23,24. As MKK4 is one
of the most consistently mutated genes across tumour types25,
concurrent inactivation of TP53 and MKK4 following HBV
integration may constitute an enabling mechanism for genome
destabilization and hepatocarcinogenesis. Consistently, patients
with HBV integration in chromosomes 2 and 17 displayed
signiﬁcantly poorer survival than in other chromosomes.
Other than inactivating tumour suppressive programs, HBV
integrations into different genomic locations can result in a
substantial enhancement of distinct oncogenic genes, which may
have a profound inﬂuence on phenotypic characteristics. In
support of this notion, a signiﬁcant proportion of HBV-associated
HCCs develop in the absence of cirrhosis. We identiﬁed several
important oncogenes preferentially affected by HBV integration
in the non-cirrhotic HCC samples, suggesting that constitutive
activation or inactivation of these genes may contribute to the
early onset of HCC without inﬂicting cirrhotic responses. Further
work is warranted to delineate the complex network of these HBV
targeted genes and its overall impact on cellular phenotype.
Collectively, our work provides a large scale and unbiased HBV
integration map in HCC, revealing the preference of integration
occurring within regions of the genome prone to DNA mutations
or rearrangements and novel target genes recurrently affected by
HBV integration. Together with the inserted HBV fragments,
these characteristics may endow HBV integration a greater
opportunity to induce crucial oncogenic alterations to host genes
in a gender- and cirrhosis-dependent manner, and eventually
leading to HCC development in patients with chronic HBV
infection.
Methods
Sample and DNA extraction. All samples were obtained from Eastern Hepato-
biliary Surgery Hospital, Shanghai, between 2009 and 2010. Tumour tissues and
paired adjacent non-tumour tissue were resected from patients undergoing primary
hepatectomy by experienced surgeons. Specimens were immediately cryopreserved
in  80 C following resection. All operations were carried out carefully to avoid
contamination between samples. DNA was extracted from paired tumour and
normal adjacent samples using Genomic DNA Mini Kit (Invitrogen, Life
Technologies) according to the manufactory’s instruction. All HBV–HCCs, and
paired adjacent non-tumour tissue are clinically and pathologically characterized
by two independent pathologists and radiologists. Demographic and clinical
features of the patients were systematically collected and summarized in
Supplementary Table 1. This study was approved by the ethical committee of
EHBH hospital and informed consent was obtained from each patient. The
inclusion criteria for this study included: (i) HBV-positive HCCs and paired
adjacent non-tumour tissues (ii) obtained from consenting patients and (iii) all
samples are HCV-negative and HIV-negative and (iv) without for autoimmune
hepatitis and metabolic and/or genetics disorders such as Wilson’s disease,
hemochromatosis.
RNA extraction and real-time quantitative PCR. Total RNAs were extracted
from tumours or paired adjacent non-tumour samples using MagMAX mirVana
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Figure 6 | HBV integration preference in male versus female HCC samples. (a) Distribution of the enriched HBV integration regions in tumour samples.
The red bars indicate the enriched regions found only in female samples, green bars represent enriched regions only found in male samples, and blue bars
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calculated by w2 test.
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Total RNA Isolation Kit (Ambion, Life Technologies) according to the manufac-
tory’s instruction. The concentration and quality of RNAs were determined by
Nanodrop 2000 (Thermo Fisher Scientiﬁc). The quantitative PCRs were performed
using Power SYBR-Green PCR Master Mix (Life Technologies, Carlsbad, CA,
USA), primer pair sets and Applied Biosystems ViiA7 Real-time System (Life
Technologies) under the conditions of 10min at 95 C followed by 40 cycles at
95 C for 15 s and at 60 C for 60 s. Beta actin was used as a housekeeping control.
The sequences of the primers are listed in Supplementary Table 2.
HBV capture experiment. We designed the sequence-capture probes according to
eight types of HBV genome (A, B, C, D, E, F, G and H) sequences and these probes
were produced by MyGenostics. DNA fragmentsB150–200 bp were obtained after
shearing genomic DNA by Covaris E-210 (Covaris, Inc., Woburn, MA). These
fragments were puriﬁed, end blunted, ‘A’ tailed and adaptor ligated. The products
of ligation were ampliﬁed by PCR and constructed into DNA sequencing library.
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA ) was used to quantify the
concentration of the DNA library. Next, hybridization was performed according to
the instruction of Target Enrichment Protocol (GenCapTM Enrichment,
MyGenostics, USA). This process was carried out at 65 C for 24 h and the
un-targeted fragments were then removed by washing buffer. These eluted
fragments were ampliﬁed by PCR and were further processed to Paired end
100-bp read-length for sequencing by the HiSeq 2000 sequencer (Illumina Inc., San
Diego, CA).
Breakpoints detection and annotation of HBV integration sites. HIVID
pipeline was used for the breakpoints detection17. First, clean reads were obtained
through removing low quality and duplicated reads, as well as adaptor-contaminated
reads. Burrows-Wheeler Aligner (BWA) was used to align clean reads onto human
(NCBI build 37, HG19) and HBV genome (AF090842.1, AB033554.1, AB014381.1,
M32138.1, AB032431.1, AB036910.1, AB064310 and AY090454.1). The paired end
reads that can be mapped to human or HBV reference genome with both ends were
removed. The remained reads were paired-end assembled to reconstruct fragment
sequences, which was to locate the position of breakpoints more precisely.
Subsequently, reference mapping was performed again to re-map the paired-end-
assembled reads onto human and HBV genome using BWA (ref. 31). The position
of a breakpoint was deﬁned as the junction of human and HBV sequence in a
paired-end-assembled read. To minimize the impact of different sequencing data
amount of each sample, the normalized support-reads number (Norm value) was
introduced, which was equal to the supported reads number of each HBV
breakpoint per million clean read pairs. The breakpoints with Norm valueZ2 were
retained. The Sanger sequencing validation rate for the selected breakpoints was
81.1%. ANNOVAR was used to do the annotation for the integrated
breakpoints17,31.
Process of detecting the integration breakpoints by RNA sequencing. We
randomly selected 12 tumour samples undergoing HIVID analysis to perform RNA
sequencing. Total RNA isolated with TRIzol reagent was treated with RNase-free
DNaseI (New England BioLabs) at 37 C for 10 min. The Dynabeads mRNA
Puriﬁcation Kit (Life Technologies) was used to isolate mRNA from the total RNA
samples. RNA-seq libraries were sequenced as paired-end 100 bp sequence tags
using the standard Solexa pipeline. Integration sites were analysed by using the
transcriptome data according to previously described method17. We removed reads
that perfectly aligned to human or HBV genome and reserved chimeric paired-end
reads. These chimeric reads were composed of both human genome sequence and
HBV genome sequence, and were used to identify HBV integration breakpoints in
the transcriptome.
PCR and sanger sequencing validation. PCR and Sanger sequencing were used
to verify the selected HBV integration breakpoints from HIVID. All the samples
used for SANGER validation are left-over samples from previous rounds of the
capture approach. PCR primers were designed based on the paired-end assembled
fragment, in which one primer located in human genome and the other in HBV
genome. PCR were performed by GeneAmp PCR System 9700 thermal cycler and
then preceded to Sanger sequencing on Applied Biosystems 3730 DNA analyzer
(Life Technologies, Inc.).
Immunohistochemical staining. Formalin ﬁxed and parafﬁn-embedded sections
(4mm) were subjected to immunohistochemical staining. The slides were incubated
overnight at 4 C with primary antibodies, including rabbit anti-AHRR (1:100,
ab108518, Abcam), rabbit anti-PTPRD(1:100, LS-B9625, LifeSpan Biosciences),
rabbit anti-NRG3(1:200, ab83704, Abcam) and mouse anti-UNC5D (1:100,
ab58141, Abcam). Anti-rabbit or anti-mouse horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were applied.
Finally, diaminobenzidine colorimetric reagent solution from Dako (Carpinteria,
CA) was used and followed by hematoxylin counterstaining (Sigma Chemical Co).
Tissue slides were scanned with an Aperio ScanScope GL, and the Aperio
ImageScope software (Aperio Technologies, Vista,CA) was used to assess the
scanned images based on the percentage of positively stained cells and staining
intensity. Expression levels of these proteins in all clinical samples were quantiﬁed.
Data availability. DNA sequencing data and RNA-seq data that support this study
have been deposited in the Sequence Read Archive (SRA) database under the
accession codes SRA335342 and SRA447498, respectively. The authors declare that
all other data is present in the Article and its Supplementary Information Files or
available from the authors upon request.
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